Not finding it? Sign in to also search OpenAlex live.
-
Abstract P1-10-01: Caveolin gene expression predicts for response and clinical outcomes of patients treated with preoperative paclitaxel-based chemotherapy regimens in early stage breast cancer2020 Cancer Research conference-abstract Biochemistry, Genetics and Molecular Biology Caveolin-1 and cellular processes
Terence Marques Williams, Andreas Schneeweiß, Christian Jackisch, Changxian Shen, Karsten Ernst Weber, Peter Andreas Fasching, +16 more
0citations -
Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial2023 Clinical Cancer Research article Biochemistry, Genetics and Molecular Biology Caveolin-1 and cellular processes Open access
Terence Marques Williams, Andreas Schneeweiß, Christian Jackisch, Changxian Shen, Karsten Ernst Weber, Peter Andreas Fasching, +16 more
7citations -
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)2024 ESMO Open article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Philipp Meyer-Wilmes, Jens Huober, Michael Untch, Jens‐Uwe Blohmer, Wolfgang Janni, Carsten Denkert, +18 more
6citations -
Magneto‐sensitive and enzymatic hydrolysis‐resistant systems for the targeted delivery of paclitaxel based on polylactide micelles with an external polyethylene oxide corona
Vladislava A. Pigareva, Yulia A. Alekhina, Irina Dmitrievna Grozdova, Xiaomin Zhu, Vasiliy V. Spiridonov, Andrey V. Sybachin
12citations -
Microfluidic formulation, cryoprotection and long-term stability of paclitaxel-loaded π electron-stabilized polymeric micelles2024 Journal of Controlled Release article Materials Science Nanoparticle-Based Drug Delivery Open access
Rahaf Mihyar, Armin Azadkhah Shalmani, Viktor Wildt, Maryam Sheybanifard, Alec Wang, Jan‐Niklas May, +16 more
11citations -
Biotin-decorated all-HPMA polymeric micelles for paclitaxel delivery2020 Journal of Controlled Release article Materials Science Nanoparticle-Based Drug Delivery Open access
Yan Wang, Mies J. van Steenbergen, Nataliia Beztsinna, Yang Mei Shi, Twan Lammers, Cornelus F. van Nostrum, +1 more
67citations -
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial2022 Clinical Cancer Research article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Monika Graeser, Oleg Gluz, Claudia Biehl, Daniel Ulbrich-Gebauer, Matthias Christgen, Jenci Palatty, +21 more
14citations -
De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.2021 Journal of Clinical Oncology conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Nadia Harbeck, Oleg Gluz, Matthias Christgen, Sherko Küemmel, Eva‐Maria Grischke, Michael S Braun, +14 more
21citations -
Riboflavin-targeted polymers improve tolerance of paclitaxel while maintaining therapeutic efficacy2024 Nanomedicine Nanotechnology Biology and Medicine article Materials Science Nanoparticle-Based Drug Delivery Open access
Milita Darguzyte, Elena Rama, Anne Rix, Jasmin Baier, Juliane Hermann, Sima Rezvantalab, +3 more
5citations -
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
Ulrike Anneliese Nitz, Oleg Gluz, Monika Graeser, Matthias Christgen, Sherko Küemmel, Eva‐Maria Grischke, +43 more
93citations -
Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”
Ulrike Anneliese Nitz, Oleg Gluz, Mathias Christgen, E.‐M. Grischke, Doris Augustin, Sherko Küemmel, +14 more
1citations -
21P BACH1 and HIF1α predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC)2021 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Cancer, Hypoxia, and Metabolism Open access
Valentina A. Vladimirova, Andreas Schneeweiß, Christian Jackisch, Karsten Ernst Weber, Carsten Denkert, Sabine Schmatloch, +13 more
0citations -
Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
Peter Andreas Fasching, Christopher W. Szeto, Carsten Denkert, Stephen Charles Benz, Karsten Ernst Weber, Patricia Spilman, +18 more
8citations -
Data from Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
Peter Andreas Fasching, Christopher W. Szeto, Carsten Denkert, Stephen Charles Benz, Karsten Ernst Weber, Patricia Spilman, +18 more
1citations -
Data from Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
Peter Andreas Fasching, Christopher W. Szeto, Carsten Denkert, Stephen Charles Benz, Karsten Ernst Weber, Patricia Spilman, +18 more
0citations -
Data from Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
Peter Andreas Fasching, Christopher W. Szeto, Carsten Denkert, Stephen Charles Benz, Karsten Ernst Weber, Patricia Spilman, +18 more
0citations -
Abstract PD5-08: Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients - An analysis of the GeparSepto trial2020 Cancer Research conference-abstract Medicine Cancer Immunotherapy and Biomarkers cited by 1 patent
Peter Andreas Fasching, Carsten Denkert, Stephen Charles Benz, Karsten Ernst Weber, Christopher W. Szeto, Jan Budczies, +17 more
1citations -
Magnetic beads for the evaluation of drug release from biotinylated polymeric micelles in biological media2022 Journal of Controlled Release article Materials Science Nanoparticle-Based Drug Delivery Open access
Yan Wang, Marcel H.A.M. Fens, Nicky C.H. van Kronenburg, Yang Mei Shi, Twan Lammers, Michal Heger, +2 more
11citations -
Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto‐GBG 84 Trial2020 Journal of the American Heart Association article Medicine Chemotherapy-induced cardiotoxicity and mitigation Open access
Alexandra Maria Rüger, Andreas Schneeweiß, Sabine Seiler, Hans Tesch, Marion van Mackelenbergh, Frederik Marmé, +14 more
38citations -
Establishment of a Pre-vascularized 3D Lung Cancer Model in Fibrin Gel—Influence of Hypoxia and Cancer-Specific Therapeutics2021 Frontiers in Bioengineering and Biotechnology article Biochemistry, Genetics and Molecular Biology Cancer, Hypoxia, and Metabolism Open access
Caroline Kniebs, Anja E. Luengen, Daniel Guenther, Christian Gabriel Cornelissen, Thomas Schmitz‐Rode, Stefan Jockenhoevel, +1 more
16citations -
Development of in vitro endothelialized drug‐eluting stent using human peripheral blood‐derived endothelial progenitor cells2020 Journal of Tissue Engineering and Regenerative Medicine article Medicine Coronary Interventions and Diagnostics
Jitsuro Tsukada, Frederic M. Wolf, Felix Jan Vogt, Nicole Schaaps, Sven Thoröe‐Boveleth, Hans Keijdener, +5 more
5citations